ENVIRONMENTAL PROTECTION AGENCY

[ER–FRL–9047–8]

Environmental Impact Statements; Notice of Availability


Weekly receipt of Environmental Impact Statements

Filed 10/28/2019 10 a.m. ET Through 11/04/2019 10 a.m. ET

Pursuant to 40 CFR 1506.9.

Notice: Section 309(a) of the Clean Air Act requires that EPA make public its comments on EISs issued by other Federal agencies. EPA’s comment letters on EISs are available at: https://cdxnodengn.epa.gov/cdx-enepa-public/action/eis/search.

EIS No. 20190268, Final Supplement, CHSRA, CA, Fresno to Bakersfield Section: Locally Generated Alternative Combined Supplemental Record of Decision and Final Supplemental Environmental Impact Statement, Contact: Dan McKell 916–330–5668

Pursuant to 23 U.S.C. 139(n)(2), CHSRA has issued a combined FEIS and ROD. Therefore, the 30-day wait/review period under NEPA does not apply to this action.


Dated: November 4, 2019.

Robert Tomiak, Director, Office of Federal Activities.

[FR Doc. 2019–24351 Filed 11–7–19; 8:45 am]

BILLING CODE 6560–50–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Delegation of Authority

Notice is hereby given that the Director, Centers for Disease Control and Prevention (CDC), has delegated to the Director, Office of Science, Deputy Director for Public Health Science and Surveillance, CDC, and the Director, Office of Technology and Innovation, Office of Science, Deputy Director for Public Health Science and Surveillance, CDC, without the authority to redelegate, all authorities to administer and make decisions regarding the invention and patent program of CDC and the authority to make determinations of rights in inventions and patents in which CDC and the Department of Health and Human Services (HHS) have an interest.

This delegation excludes the authority under 35 U.S.C. 203 (March-in Rights) and the authority to submit reports to Congress.

In addition, this delegation excludes those authorities under the Stevenson- Wydler Technology Act of 1980, as amended by the Federal Technology Transfer Act of 1986 and the National Technology Transfer and Advancement Act of 1995, which are governed by a separate delegation.

The exercise of this authority must be in accordance with applicable laws, regulations, and policies and instructions from the Office of Government Ethics, U.S. Office of Personnel Management, and HHS.

2

This delegation supersedes the Delegation of Authority Concerning Patents and Inventions dated November 14, 2012, from the Director, CDC.

This delegation became effective on October 23, 2019. In addition, the Director, CDC, hereby adopts any actions taken that involve the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: November 5, 2019.

Robert K. McGowan, Chief of Staff, Centers for Disease Control and Prevention.

[FR Doc. 2019–24402 Filed 11–7–19; 8:45 am]

BILLING CODE 4153–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Designation of a Class of Employees for Addition to the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: HHS gives notice of a decision to designate a class of employees from the West Valley Demonstration Project in West Valley, New York, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Delegation of Authority

Notice is hereby given that the Director, Centers for Disease Control and Prevention (CDC), has delegated to the Director, Office of Science, Deputy Director for Public Health Science and Surveillance, CDC, and the Director, Office of Technology and Innovation, Office of Science, Deputy Director for Public Health Science and Surveillance, CDC, without the authority to redelegate, all authorities to administer and make decisions regarding the invention and patent program of CDC and the authority to make determinations of rights in inventions and patents in which CDC and the Department of Health and Human Services (HHS) have an interest.

This delegation excludes the authority under 35 U.S.C. 203 (March-in Rights) and the authority to submit reports to Congress.

In addition, this delegation excludes those authorities under the Stevenson- Wydler Technology Act of 1980, as amended by the Federal Technology Transfer Act of 1986 and the National Technology Transfer and Advancement Act of 1995, which are governed by a separate delegation.

The exercise of this authority must be in accordance with applicable laws, regulations, and policies and instructions from the Office of Government Ethics, U.S. Office of Personnel Management, and HHS.

2

This delegation supersedes the Delegation of Authority Concerning Patents and Inventions dated November 14, 2012, from the Director, CDC.

This delegation became effective on October 23, 2019. In addition, the Director, CDC, hereby adopts any actions taken that involve the exercise of the authorities delegated herein prior to the effective date of the delegation.

Dated: November 5, 2019.

Robert K. McGowan, Chief of Staff, Centers for Disease Control and Prevention.

[FR Doc. 2019–24402 Filed 11–7–19; 8:45 am]

BILLING CODE 4153–18–P